Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Gene...( SAN FRANCISCO July 31 --...),Health

SAN FRANCISCO, July 31 /PRNewswire-USNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI) today announced the execution of a letter of intent (LOI) to collaborate with Response Genetics, Inc. (Nasdaq: RGDX) on molecular diagnostic testing and banking of advanced-stage Lung Cancer tissues.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090731/DC55399LOGO)

Specific molecular features of tumors, including EGFR mutations, ras mutations, ERCC1, RRM1 or TS overexpression, have been shown in multiple studies to have prognostic importance and/or be associated with benefit from specific interventions, as described in the NCCN 2009 Clinical Practice Guidelines in Oncology. Currently, only a minority of patients with Lung Cancer, especially advanced stage disease, are having these molecular assessments performed. As a result of ALCMI's efforts to address this inequity, RGI will employ its panel of clinically-validated genetic tests -- ResponseDX: Lung(TM) -- and rapidly communicate the results with the patients' physicians. "We are thrilled to collaborate with Response Genetics, and as a Lung Cancer survivor I know first-hand just how critical these tests will be to bringing the right therapies to each patient in a time-sensitive manner," said Bonnie J. Addario, founder of ALCMI and the Bonnie J. Addario Lung Cancer Foundation.

"We are extremely pleased to be working with ALCMI to help make personalized medicine a reality for Lung Cancer patients," said Kathleen Danenberg, Response Genetics' president and CEO.

The lack of biospecimens from Lung Cancer patients with advanced diseas
'/>"/>